Logo image of CLYM

CLIMB BIO INC (CLYM) Stock Fundamental Analysis

NASDAQ:CLYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD

1.37  -0.05 (-3.52%)

After market: 1.37 0 (0%)

Fundamental Rating

3

Overall CLYM gets a fundamental rating of 3 out of 10. We evaluated CLYM against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CLYM as it has an excellent financial health rating, but there are worries on the profitability. CLYM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLYM has reported negative net income.
In the past year CLYM has reported a negative cash flow from operations.
In the past 5 years CLYM always reported negative net income.
CLYM had a negative operating cash flow in each of the past 5 years.
CLYM Yearly Net Income VS EBIT VS OCF VS FCFCLYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CLYM's Return On Assets of -46.32% is in line compared to the rest of the industry. CLYM outperforms 51.61% of its industry peers.
With a decent Return On Equity value of -48.08%, CLYM is doing good in the industry, outperforming 66.31% of the companies in the same industry.
Industry RankSector Rank
ROA -46.32%
ROE -48.08%
ROIC N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
CLYM Yearly ROA, ROE, ROICCLYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLYM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLYM Yearly Profit, Operating, Gross MarginsCLYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

CLYM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLYM has more shares outstanding
CLYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLYM Yearly Shares OutstandingCLYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLYM Yearly Total Debt VS Total AssetsCLYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 5.86 indicates that CLYM is not in any danger for bankruptcy at the moment.
CLYM has a Altman-Z score of 5.86. This is in the better half of the industry: CLYM outperforms 79.21% of its industry peers.
CLYM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.86
ROIC/WACCN/A
WACCN/A
CLYM Yearly LT Debt VS Equity VS FCFCLYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

CLYM has a Current Ratio of 14.25. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 14.25, CLYM belongs to the best of the industry, outperforming 86.56% of the companies in the same industry.
CLYM has a Quick Ratio of 14.25. This indicates that CLYM is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 14.25, CLYM belongs to the best of the industry, outperforming 86.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.25
Quick Ratio 14.25
CLYM Yearly Current Assets VS Current LiabilitesCLYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

CLYM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -347.79%.
EPS 1Y (TTM)-347.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-401.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CLYM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.65% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.68%
EPS Next 2Y17.97%
EPS Next 3Y9.65%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLYM Yearly EPS VS EstimatesCLYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLYM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLYM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLYM Price Earnings VS Forward Price EarningsCLYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLYM Per share dataCLYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.97%
EPS Next 3Y9.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLYM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLIMB BIO INC

NASDAQ:CLYM (7/15/2025, 5:20:01 PM)

After market: 1.37 0 (0%)

1.37

-0.05 (-3.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)N/A N/A
Inst Owners85.02%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner Change39.03%
Market Cap92.58M
Analysts87.5
Price Target10.2 (644.53%)
Short Float %2.27%
Short Ratio5.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-43.79%
Min EPS beat(2)-102.61%
Max EPS beat(2)15.03%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2.78%
EPS NQ rev (3m)-23.33%
EPS NY rev (1m)-1.12%
EPS NY rev (3m)-36.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 0.48
EV/EBITDA N/A
EPS(TTM)-2.37
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS2.86
TBVpS2.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.32%
ROE -48.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.11%
ROA(5y)-44.53%
ROE(3y)-34.22%
ROE(5y)-48.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.25
Quick Ratio 14.25
Altman-Z 5.86
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-347.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-401.63%
EPS Next Y42.68%
EPS Next 2Y17.97%
EPS Next 3Y9.65%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-179.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.15%
OCF growth 3YN/A
OCF growth 5YN/A